Wednesday, December 26, 2007

Corneal CrossLinking With Riboflavin For Keratoconus

Collagen Cross-Linking with Riboflavin(also known as С3-R ,UVX and now CXL) -

A new hope for Keratoconus patients

There is finally some good news for patients with keratoconus and their physicians.

Corneal Collagen Cross-linking using Riboflavin involves application of Riboflavin drops to the cornea, followed by exposure of the cornea to low dose ultraviolet A light. The activated riboflavin induces collagen fibrils(glue that holds the body together) to thicken, stiffen, & re-attach i.e. cross-link to each other creating new bonds between the adjacent collagen molecules leading to increase in the rigidity and thereby rendering cornea less malleable.

Keratoconus, a ectatic corneal disease usually progresses in the younger age group

Earlier ,the only way to make the patient see better was by fitting special contact lenses, intracorneal rings or if all else failed a lamellar or full thickness corneal transplant.

These surgical treatments have their limitations and need for lifelong care and follow up.

This is the only procedure which eventually stops/ delays the progression of Corneal ectasia and this helps in stable fitting for Contact lenses and glasses and most importantly to delay and in come cases avoid a corneal transplant.

Advantages of CrossLinking Treatment with Riboflavin

· Causes an increase in corneal stiffness of the anterior 200-250 μm

· Deeper structures don‘t get damaged

· Simple one time treatment

· Halts the progress and causes some regression

· No injection , No stitches & No incisions as in Keratoplasty

· Quick & Easy treatment with low costs.

Cutting Edge Laser Technology available at RF

PASCAL Multispot Laser Photocoagulator

For faster and more accurate treatment of various retinal and eye conditions .

(First Installation in India at Retina Foundation in September 2007.)

The PASCAL Photocoagulator is an integrated semi-automatic pattern scan laser photocoagulation system designed to treat ocular diseases using a single shot or predetermined pattern array.

Pascal photocoagulator also has [CE Mark] for international sale.

The Pascal method of photocoagulation was initially developed at Stanford University. OptiMedica founders worked together at Coherent, and based on their experience in the ophthalmic laser industry, recognized the need for improved safety, precision, comfort and speed of photocoagulation procedures for eye diseases.

  • In 2007, OptiMedica received the R&D 100 award for the Pascal Photocoagulator. The award recognizes the innovative technology as one of the top 100 products introduced to the marketplace in the last year.
  • The Pascal Photocoagulator was recognized with a 2007 Medical Design Excellence Award gold medal in the surgical equipment, instruments, and supplies category.